Slingshot members are tracking this event:
Novartis' (NVS) Gets Priority Review for Ribociclib Marketing Application in First-Line Treatment of HR+/HER2- Advanced Breast Cancer
Slingshot Insights Explained
Nov 01, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Priority Review, Ribociclib, Marketing Application, First-line Treatment, Hr+/her2- Advanced Breast Cancer